These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. Huang Z, Xu D, Zhang F, Ying Y, Song L. Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220 [Abstract] [Full Text] [Related]
6. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Korkmaz ET, Koksal D, Aksu F, Dikmen ZG, Icen D, Maden E, Onder S, Akbiyik F, Emri S. Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229 [Abstract] [Full Text] [Related]
10. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. Kim HR, Oh IJ, Shin MG, Park JS, Choi HJ, Ban HJ, Kim KS, Kim YC, Shin JH, Ryang DW, Suh SP. J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852 [Abstract] [Full Text] [Related]
12. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency]. Shen D, Han BB, Chen F, Wei BJ, Cui CJ, Wang GJ, Cui W. Zhonghua Yi Xue Za Zhi; 2017 Sep 12; 97(34):2657-2662. PubMed ID: 28910952 [Abstract] [Full Text] [Related]
14. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Hirose T, Okuda K, Yamaoka T, Ishida K, Kusumoto S, Sugiyama T, Shirai T, Ohnshi T, Ohmori T, Adachi M. Lung Cancer; 2011 Feb 12; 71(2):224-8. PubMed ID: 20537424 [Abstract] [Full Text] [Related]
15. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer. Li L, Zhang Q, Wang Y, Xu C. J Clin Lab Anal; 2023 Apr 12; 37(7):e24865. PubMed ID: 37088873 [Abstract] [Full Text] [Related]
17. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X. Tumour Biol; 2009 Apr 12; 30(3):121-9. PubMed ID: 19506400 [Abstract] [Full Text] [Related]
18. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Clin Cancer Res; 2008 Dec 01; 14(23):7813-21. PubMed ID: 19047109 [Abstract] [Full Text] [Related]
20. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy. Liu X, Zhang W, Yin W, Xiao Y, Zhou C, Hu Y, Geng S. Medicine (Baltimore); 2017 Nov 01; 96(46):e8258. PubMed ID: 29145241 [Abstract] [Full Text] [Related] Page: [Next] [New Search]